Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freshworks Inc (FRSH) vs Merck & Co., Inc. (MRK) Price & Performance

Freshworks IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Freshworks Inc vs Merck & Co., Inc. — how do they compare? Freshworks Inc trades at $13.9 (market cap $3.56B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 98.7× Freshworks Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Merck & Co., Inc. for 98 Days on average.

FRSHMRK
Market Cap
$3.56B$351.28B
Volume
9,066,4547,969,665
Sector
TechnologyHealth
52-Week High
$13.92$156.43
52-Week Low
$6.88$82.49
Typical Hold Time
39 Days98 Days
Enterprise Value
$2.93B$398.04B
Dividend Yield
—2.39%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freshworks Inc

Freshworks (FRSH) trades at $13.86, up 1.91% today, reflecting positive momentum following its Q2 2026 earnings beat. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests it may be approaching overbought territory. Fundamentally, the company has achieved a significant turnaround, posting its first GAAP profitable quarter in 2026 with revenue growth of 16% year-over-year, driven by strength in its employee experience portfolio and cost discipline.

The outlook is positive, supported by a 50% analyst buy rating and a consensus price target of $14.60, implying modest upside. Key opportunities include continued AI monetization and market share gains, while risks involve heightened competition in the SaaS sector and the need to sustain recent profitability improvements amid economic uncertainty.

Merck & Co., Inc.

Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.

The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FRSH
0% Buy100% Sell
Avg holding period · 39 Days
MRK
60% Buy40% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About Freshworks Inc

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.

Read more on FRSH →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →